In a Phase Ib study evaluating the combination of venetoclax with tamoxifen in estrogen receptor (ER)-positive, BCL-2 positive, metastatic breast cancer, promising anti-tumor activity was noted (57). This evidence concerns the gene ESR1 and neoplasm.